Literature DB >> 9751782

Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias.

T Hershey1, K J Black, M K Stambuk, J L Carl, L A McGee-Minnich, J S Perlmutter.   

Abstract

Parkinson's disease (PD) is a progressive neurologic condition characterized by tremor, slowness, stiffness, and unstable posture. Degeneration of dopamine-producing neurons in the substantia nigra causes PD. Treatment with levodopa, a precursor of dopamine, initially ameliorates the clinical manifestations of PD. However, chronic levodopa treatment can produce severe involuntary movements (so-called dopa-induced dyskinesias or DID), limiting treatment. Pallidotomy, placement of a surgical lesion in the internal segment of the globus pallidus, reduces DID. Because this result is inconsistent with current theories of both basal ganglia function and DID, it prompted us to investigate the brain's response to levodopa. We measured regional cerebral blood flow response to levodopa with positron-emission tomography in 6 PD patients with DID, 10 chronically treated PD patients without DID, 17 dopa-naïve PD patients, and 11 normals. The dose of levodopa was chosen to produce clinical benefit without inducing DID. This strategy allowed us to examine the brain response to levodopa across groups without the confounding effect of differences in motor behavior. We found that the DID group had a significantly greater response in ventrolateral thalamus than the other groups. This was associated with decreased activity in primary motor cortex. These findings are consistent with increased inhibitory output from the internal segment of the globus pallidus to thalamus after levodopa administration. They provide a physiological explanation for the clinical efficacy of pallidotomy and new insights into the physiology of the basal ganglia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751782      PMCID: PMC21757          DOI: 10.1073/pnas.95.20.12016

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

3.  Aromatic amino acids and modification of parkinsonism.

Authors:  G C Cotzias; M H Van Woert; L M Schiffer
Journal:  N Engl J Med       Date:  1967-02-16       Impact factor: 91.245

4.  A stereotactic method of anatomical localization for positron emission tomography.

Authors:  P T Fox; J S Perlmutter; M E Raichle
Journal:  J Comput Assist Tomogr       Date:  1985 Jan-Feb       Impact factor: 1.826

5.  Brain blood flow measured with intravenous H2(15)O. I. Theory and error analysis.

Authors:  P Herscovitch; J Markham; M E Raichle
Journal:  J Nucl Med       Date:  1983-09       Impact factor: 10.057

6.  Brain blood flow measured with intravenous H2(15)O. II. Implementation and validation.

Authors:  M E Raichle; W R Martin; P Herscovitch; M A Mintun; J Markham
Journal:  J Nucl Med       Date:  1983-09       Impact factor: 10.057

7.  The distribution of alterations in energy metabolism in the rat brain produced by apomorphine.

Authors:  J McCulloch; H E Savaki; M C McCulloch; J Jehle; L Sokoloff
Journal:  Brain Res       Date:  1982-07-08       Impact factor: 3.252

8.  Increased glucose metabolism during long-duration recurrent inhibition of hippocampal pyramidal cells.

Authors:  R F Ackermann; D M Finch; T L Babb; J Engel
Journal:  J Neurosci       Date:  1984-01       Impact factor: 6.167

9.  Retina-dependent activation by apomorphine of metabolic activity in the superficial layer of the superior colliculus.

Authors:  J McCulloch; H E Savaki; M C McCulloch; L Sokoloff
Journal:  Science       Date:  1980-01-18       Impact factor: 47.728

10.  Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat.

Authors:  W J Schwartz; C B Smith; L Davidsen; H Savaki; L Sokoloff; M Mata; D J Fink; H Gainer
Journal:  Science       Date:  1979-08-17       Impact factor: 47.728

View more
  20 in total

1.  Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease.

Authors:  K Elisabet Ohlin; Irene Sebastianutto; Chris E Adkins; Cornelia Lundblad; Paul R Lockman; M Angela Cenci
Journal:  Neuroimage       Date:  2012-03-03       Impact factor: 6.556

2.  A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist.

Authors:  Kevin J Black; Tamara Hershey; Jonathan M Koller; Tom O Videen; Mark A Mintun; Joseph L Price; Joel S Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

Review 3.  Critical involvement of the motor cortex in the pathophysiology and treatment of Parkinson's disease.

Authors:  David Lindenbach; Christopher Bishop
Journal:  Neurosci Biobehav Rev       Date:  2013-10-07       Impact factor: 8.989

4.  Postprandial plasma PYY concentrations are associated with increased regional gray matter volume and rCBF declines in caudate nuclei--a combined MRI and H2(15)O PET study.

Authors:  Christopher M Weise; Pradeep Thiyyagura; Eric M Reiman; Kewei Chen; Jonathan Krakoff
Journal:  Neuroimage       Date:  2011-12-21       Impact factor: 6.556

5.  Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease.

Authors:  Kevin J Black; Jonathan M Koller; Meghan C Campbell; Debra A Gusnard; Stephen I Bandak
Journal:  J Neurosci       Date:  2010-12-01       Impact factor: 6.167

6.  Little Change in Functional Brain Networks Following Acute Levodopa in Drug-Naïve Parkinson's Disease.

Authors:  Robert L White; Meghan C Campbell; Dake Yang; William Shannon; Abraham Z Snyder; Joel S Perlmutter
Journal:  Mov Disord       Date:  2019-12-19       Impact factor: 10.338

7.  Emergent Functional Network Effects in Parkinson Disease.

Authors:  Caterina Gratton; Jonathan M Koller; William Shannon; Deanna J Greene; Baijayanta Maiti; Abraham Z Snyder; Steven E Petersen; Joel S Perlmutter; Meghan C Campbell
Journal:  Cereb Cortex       Date:  2019-06-01       Impact factor: 5.357

8.  The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.

Authors:  David Lindenbach; Melissa M Conti; Corinne Y Ostock; Jessica A George; Adam A Goldenberg; Mitchell Melikhov-Sosin; Emily E Nuss; Christopher Bishop
Journal:  J Neurosci       Date:  2016-09-21       Impact factor: 6.167

9.  Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon.

Authors:  Clemence Simonin; M Tir; D Devos; A Kreisler; K Dujardin; J Salleron; A Delval; S Blond; L Defebvre; A Destée; P Krystkowiak
Journal:  J Neurol       Date:  2009-06-18       Impact factor: 4.849

10.  Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease.

Authors:  Shigeki Hirano; Kotaro Asanuma; Yilong Ma; Chengke Tang; Andrew Feigin; Vijay Dhawan; Maren Carbon; David Eidelberg
Journal:  J Neurosci       Date:  2008-04-16       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.